inControl Advice Study

Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes

This study, designed for patients using multiple daily injections (MDI), is evaluating the inControl Advice system from TypeZero, which includes smart insulin pens, a Dexcom G5, and an Android phone with the TypeZero inControl algorithm. Participants are randomized either to the control group, which continues MDI treatment as usual, or the treatment group, which uses the inControl Advice system to receive dosage recommendations. The study lasts for 3.5 months, and all supplies and insulin are provided by the study.

• Participant must be 15 years or older
• Must have been diagnosed with type 1 diabetes for at least one year
• Using basal and meal insulin and carb counting for at least 1 month
• Willingness to use Tresiba and Novolog insulins for the duration of the study
• Ability ot access the internet to provide data to the clinical team, and to travel to the research site. 

• Medical need for chronic acetaminophen 
• Use of any medication that is deemed to interfere with the trial, for example oral steroids
• Coronary artery disease, heart failure
• Hemophilia or any other bleeding disorder
• Participation in another pharmaceutical or device trial at the time of enrollment or during the study
•  

We will be enrolling for this study through the end of June 2018. If you're interested in learning more about this study, please reach out to the research coordinator listed on the right. You may also download the consent form, assent form, and any other documents linked on the right.